Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Chief Commercial Officer | June 14, 2024 | June 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date June 14, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2033-12-15 | Direct | 260,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 260,000 · Balance 260,000 F1: This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2: This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024.
F2: This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 18, 2024 21:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001104659-24-072885 · tm2417520-6_4seq1.xml · derivative · entry 1 Lea Darrell Shane · CIK 0001958526 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2033-12-15 F1 · date: This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:09 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon Stock | 39,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-125488 · tm2332764-3_4seq1.xml · nonDerivative · entry 1 Lea Darrell Shane · CIK 0001958526 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,599 Read SEC document |
| June 23, 2023 Filed Dec 13, 2023 01:09 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-23-125488 · tm2332764-3_4seq1.xml · derivative · entry 2 Lea Darrell Shane · CIK 0001958526 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-17 F1 · date: This option was contingently granted on January 16, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2023 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 23, 2023. Because January 16, 2023 was a federal holiday, the option was priced on the following trading day. F2 · derivative.exercise_date: This option shall vest over a period of three years from January 17, 2023, with 1/3 vesting on the first anniversary of January 17, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of January 17, 2023. Read SEC document |
| November 21, 2022 Filed Dec 15, 2022 22:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001140361-22-045712 · form4.xml · derivative · entry 1 Lea Darrell Shane · CIK 0001958526 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-11-21 F1 · derivative.exercise_date: This option shall vest in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continuous employment by the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.